Effect of fusidic acid ointment combined with compound clobetasol propionate ointment in treatment of hand and foot keratotic eczema
SHU Xin1, TU Xiaojuan1, CHEN Xiaoxia2, ZHANG Wei1, YANG Yina1, ZHENG Jiao3
1. Department of Dermatology, 2. Department of Radiology, 3. Department of General Practice, the Third Medical Center of PLA General Hospital, Beijing 100039, China
Abstract：Objective To analyze the effect of fusidic acid ointment combined with compound clobetasol propionate ointment in the treatment of hand and foot keratotic eczema.Methods Eighty patients with hand-foot keratotic eczema admitted to the Third Medical Center of PLA General Hospital were randomly divided into a control group (42 cases) and an observation group (42 cases). The control group was treated with compound clobetasol propionate ointment, while the observation group was treated with fusidic acid ointment combined with compound clobetasol propionate ointment. The course of treatment lasted for 4 weeks. The pruritus, eczema area and severity index(EASI) ,dermatological quality of life scale (DLQI) scores, inflammatory factors IL-2、IL-4、IL-5 and TNF-αwere compared between the two groups before and after 4 weeks of treatment, and the efficacy and safety of the two groups were also evaluated.Results The effective rate of treatment in the observation group was 88.10%, which was higher than 71.43% in the control group (P<0.05). After 4 weeks, the observation group's pruritus scores[(1.12±0.26)], EASI scores[(3.25±0.77)]and DLQI scores[(16.34±3.28)]were all lower than those of the control group[respectively(1.44±0.38),(5.33±1.12) and(18.78±3.67)] (P<0.05). Inflammatory factors IL-2, IL-4, IL-5 and TNF-α in the observation group were also lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (9.52% vs. 4.76%).Conclusions Fusidic acid ointment combined with compound clobetasol propionate ointment in the treatment of hand and foot keratotic eczema, which can reduce allergy and inflammation and can also reduce itching significantly, is effective and safe.
Agner T,Aalto-Korte K, Andersen K E, et al. Factors associated with combined hand and foot eczema[J].J Eur Acad Dermatol Venereol, 2017, 31(5): 828-832.
[3]
Yamada K, Matsushita K, Wang J, et al. Topical glucose induces caudin-1 and filaggrin expression in a mouse model of atopic dermatitis and in keratinocyte culture, exerting anti-inflammatory effects by repairing skin barrier function[J]. Acta Derm Venereol,2018,98(1):19-25.
[4]
Rademaker M,Armour K,Baker C, et al.Management of chronic hand and foot eczema. An Australia/New Zealand Clinical narrative[J]. Australas J Dermatol, 2021,62(1):17-26
[5]
余艺昕,杨 斌.手湿疹中外诊疗指南概述[J].中华皮肤科杂志,2019,52(1):53-56.
[6]
Bartosíková L, Frána L, Necas J, et al. Prednicarbate and cetirizin dihydrochloride in the treatment of atopic eczema in the acute phase in children[J]. Ceska Slov Farm, 2018, 50(1): 38-40.
[7]
Bonamonte D, Belloni Fortina A, Neri L, et al. Fusidic acid in skin infections and infected atopic eczema[J]. G Ital Dermatol Venereol, 2014, 149(4): 453-459.
Elsner P, Agner T. Hand eczema: treatment[J]. J Eur Acad Dermatol Venereol, 2020, 34(Suppl 1):13-21.
[11]
Coenraads P J. Hand eczema[J]. N Engl J Med. 2012, 367(19):1829-1837.
[12]
Agrawal P V, Sharma Y K,Kumar A, et al. Comparative analysis of epidemiological data as well as quality of life in patients having hand eczema vis-à-vis foot eczema[J]. Indian Dermatol Online J, 2019, 10(5): 519-523.
Takeuchi A, Oguri T, Sone K, et al. Predictive and prognostic value of CYFRA 21-1 for advanced non-small cell lung cancer treated with EGFR-TKIs[J]. Anticancer Res, 2017, 37(10):5771-5776.
Tsoi L C, Rodriguez E, Stölzl D, et al. Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses[J]. J Allergy Clin Immunol, 2020, 145(5): 1406-1415.
[18]
Wang S, Zhu R, Gu C, et al. Distinct clinical features and serum cytokine pattern of elderly atopic dermatitis in China[J]. J Eur Acad Dermatol Venereol, 2020,34(10):2346-2352.
2022, Vol. 33 
